# Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

> **NCT03317743** · PHASE1 · COMPLETED · sponsor: **Idience Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** NOV140101 (IDX-1197)

## Key facts

- **NCT ID:** NCT03317743
- **Lead sponsor:** Idience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-29
- **Primary completion:** 2020-12-08
- **Final completion:** 2021-10-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03317743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03317743, "Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03317743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*